(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of 18.61% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Dynavax Technologies's revenue in 2024 is $232,284,000.On average, 2 Wall Street analysts forecast DVAX's revenue for 2024 to be $36,110,412,941, with the lowest DVAX revenue forecast at $35,670,894,233, and the highest DVAX revenue forecast at $36,549,931,649. On average, 2 Wall Street analysts forecast DVAX's revenue for 2025 to be $42,483,107,667, with the lowest DVAX revenue forecast at $41,015,650,703, and the highest DVAX revenue forecast at $43,950,564,630.
In 2026, DVAX is forecast to generate $49,462,508,009 in revenue, with the lowest revenue forecast at $46,925,969,136 and the highest revenue forecast at $51,999,046,881.